RxDoctor Payments Data

Virany Kreng, MD

Family Medicine · Orange, CANPI 1891881660

Payments from drug & device makers

$700in general payments, 2019–2025

Across 28 payments — averaging $24.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$173
  • Teva Pharmaceuticals USA, Inc.$149
  • Novo Nordisk$83
  • Amgen$74
  • AstraZeneca$67
  • GSK$39
  • plus $115 from 6 others

What the payments were for

  • Consulting fees$122%
  • Food & beverage$68898%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$700 in reported general payments places this provider in the 65th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$24,865
Medicare patients
82
Services billed
268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban38$33,377
OzempicSemaglutide21$19,550
Levothyroxine Sodium118$1,500
Atorvastatin Calcium159$1,338
Metoprolol Succinate70$1,185
Losartan Potassium68$809
Omeprazole55$750
Rosuvastatin Calcium61$722
Gabapentin22$703
Fluoxetine Hcl23$686
Duloxetine Hcl33$672
Benazepril Hcl86$632
Amlodipine Besylate157$627
Lisinopril61$574
Azelastine Hcl28$463

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$33,37738 claims
Novo NordiskOzempic$83$19,55021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,533 family medicine providers in California.

Other family medicine in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →